Oculoplastics News

VRDN-001 demonstrated positive results at a low dose for the treatment of active thyroid eye disease in a phase 1/2 clinical trial, according to a press release from Viridian Therapeutics.

Individualized care and patient satisfaction are among the areas of emphasis in a new consensus statement on management of thyroid eye disease.

Less than 5% of adults with thyroid eye disease who completed a full course of teprotumumab therapy required an additional course of the agent, according to a presenter at the American Thyroid Association annual meeting.

CHICAGO — Commercial insurer payments for teprotumumab vary dramatically, with cost influencing access to care and cost-effectiveness, according to a study presented at the ASOPRS Fall Scientific Symposium.

CHICAGO — New target therapies and improvements in surgical techniques are leading to a change in the expectations and outcomes of patients with thyroid eye disease.

CHICAGO — There is room for improvement to make oculoplastics education materials more readable and accountable, according to a study presented here.

DENVER — While rare, platelet-rich plasma injections can sometimes affect vision loss, suggesting similar precautions be used as with facial fillers, according to a study presented here.

CHICAGO — Patients who received Tepezza to treat thyroid eye disease showed improved extraocular muscle size that correlated to improved diplopia and motility, according to a presenter here.

CHICAGO — Biologics are a game changer for the treatment of thyroid eye disease, according to one speaker at the American Academy of Ophthalmology meeting.

CHICAGO — Pretreatment evaluation of fat-to-muscle ratio in thyroid eye disease will allow for the best treatment choice, a presenter here said.